Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
4.491
Zitationen
23
Autoren
2014
Jahr
Abstract
In patients with idiopathic pulmonary fibrosis, nintedanib reduced the decline in FVC, which is consistent with a slowing of disease progression; nintedanib was frequently associated with diarrhea, which led to discontinuation of the study medication in less than 5% of patients. (Funded by Boehringer Ingelheim; INPULSIS-1 and INPULSIS-2 ClinicalTrials.gov numbers, NCT01335464 and NCT01335477.).
Ähnliche Arbeiten
An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management
2011 · 7.206 Zit.
Interpretative strategies for lung function tests
2005 · 5.912 Zit.
Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage
2019 · 5.046 Zit.
Cellular and molecular mechanisms of fibrosis
2007 · 4.387 Zit.
Fleischner Society: Glossary of Terms for Thoracic Imaging
2008 · 4.218 Zit.
Autoren
- Luca Richeldi
- Roland M. du Bois
- Ganesh Raghu
- Arata Azuma
- Kevin M. Brown
- Ulrich Costabel
- Vincent Cottin
- Kevin Flaherty
- David M. Hansell
- Yoshikazu Inoue
- Dong Soon Kim
- Martin Kolb
- Andrew G. Nicholson
- Paul W. Noble
- Moisés Selman
- Hiroyuki Taniguchi
- Michèle Brun
- Florence Le Maulf
- M Girard
- Susanne Stowasser
- Rozsa Schlenker‐Herceg
- Bernd Disse
- Harold R. Collard
Institutionen
- NIHR Southampton Respiratory Biomedical Research Unit(GB)
- National Institute for Health Research(GB)
- University of Southampton(GB)
- Imperial College London(GB)
- Seattle University(US)
- University of Washington(US)
- Nippon Medical School(JP)
- University of Colorado Denver(US)
- National Jewish Health(US)
- University of Duisburg-Essen(DE)
- Ruhrlandklinik(DE)
- Hôpital Louis Pradel(FR)
- Université Claude Bernard Lyon 1(FR)
- Michigan Medicine(US)
- Royal Brompton & Harefield NHS Foundation Trust(GB)
- Lung Institute(US)
- National Kinki Chuo Hospital for Chest Disease(JP)
- University of Ulsan(KR)
- Asan Medical Center(KR)
- McMaster University(CA)
- Cedars-Sinai Medical Center(US)
- Instituto Nacional de Enfermedades Respiratorias(MX)
- Tosei General Hospital(JP)
- Boehringer Ingelheim (Egypt)(EG)
- Boehringer Ingelheim (Germany)(DE)
- Boehringer Ingelheim (United States)(US)
- University of California, San Francisco(US)